Individuals Discontinuing Slimming Jabs Gain Back Weight at a Quadrupled Rate Than Dieters

Fresh analysis suggests that patients who stop using blockbuster slimming jabs like Wegovy and Mounjaro can put back on lost weight much more quickly than those who halt conventional diet and exercise regimens.

Findings released in a leading medical journal shows that while overweight individuals can lose substantial amounts of their body weight while using the jabs, the mass returns at an average rate of nearly a kilo each month once they quit.

"Individuals purchasing these medications should be cognizant of the danger of quick rebound weight gain when the therapy concludes," warns lead investigator Dr. Susan Jebb.

Such speed of regain means a reversion to starting weight in about a year and a half.

Weighing Therapies

The study, which looked at 37 of trials involving thousands of participants, compared the effects of GLP-1 agonists with other pills.

Scientists note that people who shed pounds through diet and exercise typically have a less rapid creep back—perhaps 100 grams monthly—after stopping.

Explaining the Quick Regain

Experts suggest the way of the injections accounts for the amplified regain.

These medications imitate a natural hormone called glucagon-like peptide-1, which controls hunger.

"Artificially providing the hormone concentrations several times higher than normal could lead to the body to produce less of its own natural GLP-1, and may also lessen sensitivity to its actions," explained Dr. Adam Collins, a dietetics expert.

"Discontinuation of this GLP-1 'fix' leads to appetite is uncontrolled, making overeating a significant risk."

A Lifelong Condition?

Health authorities suggest the injections for people with weight-linked medical conditions, accompanied by prescribed diet and exercise modifications.

Professionals argue that, given the significant potential of weight regain, the treatment is often ongoing.

This perspective is reinforced by drug manufacturers, who say that the findings "emphasize the chronic character of obesity," comparing it to managing diseases like high blood pressure.

User Accounts

Individuals who have discontinued the medication report a intense resurgence of appetite.

"I experienced a trigger that goes on and you become extremely hungry," said a patient.

This challenge is worsened if patients have not adopted lasting dietary or behavioural modifications during treatment.

Growing Use

Survey data show that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire continuing to grow.

• Use is more common among women than men.
• The middle-aged demographic shows the greatest usage rates.
• A large proportion access the medications through private healthcare rather than public health services.

In conclusion, clinicians stress that while GLP-1 drugs are potent tools for weight loss, they are not a standalone cure and maintained weight loss relies on combined behavioural changes.